Skip to content
POM-V Prescription Required Companion Animal

Nobivac DHP

Active ingredients: Canine adenovirus, Canine distemper virus, Canine parvovirus

Form

Injection

Species

Dogs

Manufacturer

Intervet International B.V.

VMD MA No.

06376/5034

What it's used for

Onset of immunity: 1 week. Duration of immunity: 3 years.

Full indications, dosage and side effects ↓
View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Canine adenovirus + Canine d...

  1. 1

    Ask your vet for a written prescription

    They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.

  2. 2

    Fill it at a registered online retailer

    The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Nobivac DHP — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Onset of immunity: 1 week.
Duration of immunity: 3 years.
Reconstitute immediately prior to use by the addition of the contents of one vial (1.0 ml)
of the solvent provided or the vaccines in the Nobivac range against rabies or
leptospirosis as mentioned in section 3.8 (where these products are authorised). Sterile
equipment should be used for administration.
Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use
chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Vaccination regime
Primary course vaccination:
A single injection should establish active immunity in dogs of 10 weeks of age or older.
Where earlier protection is required a first dose may be given to puppies from 6 weeks
of age, but because maternally derived passive antibody can interfere with the response
to vaccination a final dose should be given 2–4 weeks later i.e. at 10 weeks of age or
older.
Booster vaccination:
To maintain protection a single booster dose is recommended every three years.
Reconstituted product: off-pink or pink coloured suspension.
None.
Dogs:
Common
(1 to 10 animals / 100 animals
Injection site swelling
.

Amended pages: August 2025
treated):Rare
(1 to 10 animals / 10,000
animals treated):
Elevated temperature
. Hypersensitivity reaction
(e.g. lethargy, facial oedema, pruritus, dyspnoea,
vomiting, diarrhoea or collapse, including
anaphylaxis)
.
Up to 5 mm in diameter. This swelling may be hard and painful and last for up to 3
days post injection.
Transient.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or the national competent authority via the
national reporting system. See the package leaflet for respective contact details.
Vaccinate healthy animals only.
The efficacy of the CDV, CAV2 and CPV components of the vaccine may be reduced
due to maternal antibody interference. However, the vaccine has been proven to be of
benefit against virulent challenge in the presence of maternal antibody levels to CDV,
CAV2 and CPV that are likely to be encountered under field conditions.

Special precautions for safe use in the target species:
Dogs should not be exposed to unnecessary risk of infection within the first week after
completion of the vaccination regimen.
While the canine parvovirus vaccine strain may be shed at very low levels for up to 8
days after inoculation, there is no evidence that this results in clinical symptoms if non-
vaccinated animals are infected.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
In case of accidental self-injection, seek medical advice immediately and show the
package leaflet or the label to the physician.
Special precautions for the protection of the environment:
Not applicable.
Other precautions:
Not applicable.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed
and administered with the inactivated vaccines in the Nobivac range against canine
leptospirosis caused by all or some of the following serovars: L. interrogans serogroup
Canicola serovar Canicola, L. interrogans serogroup Icterohaemorrhagiae serovar
Copenhageni, L. interrogans serogroup Australis serovar Bratislava, and L. kirschneri
serogroup Grippotyphosa serovar Bananal/Liangguang.
After administration with one of the leptospirosis vaccines, a mild and transient increase
in body temperature (≤ 1°C) may occur for a few days after vaccination, with some pups
showing less activity and/or a reduced appetite. A small transient swelling 4 cm),
which can occasionally be firm and painful on palpation, may be observed at the site of
injection. Any such swelling will either have disappeared or be clearly diminished by 14
days post-vaccination.
After mixed administration of an overdose of this vaccine and an overdose of the
leptospirosis vaccines in the Nobivac range, transient local reactions such as diffuse to
firm swellings from 1 to 5 cm in diameter may be observed, usually these will persist no
longer than 5 weeks, however some may take a little longer to completely disappear.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed
and administered with the inactivated vaccine in the Nobivac range against rabies. After
administration with the rabies vaccine, where this product is authorised, transient local
reactions such as diffuse to firm swellings from 1 to 4 cm in diameter may be observed
for up to 3 weeks after vaccination. The swellings may be painful for up to 3 days post
dosing.

Amended pages: August 2025
Safety and efficacy data are available which demonstrate that this vaccine can be
administered on the same day, but not mixed, with the live vaccine for intranasal
administration in the Nobivac range against infectious tracheobronchitis caused by
Bordetella bronchiseptica and/or canine parainfluenza virus.
Safety and efficacy data are available which demonstrate that this vaccine can be
administered at the same time but not mixed with the inactivated vaccine in the Nobivac
range against Bordetella bronchiseptica.
When this vaccine is used with any of the other Nobivac vaccines referred to above, the
minimum vaccination age for each vaccine must be taken into account such that at the
time of vaccination, the dogs are at or older than the oldest minimum vaccination age
for the individual vaccines.
Consult product leaflets before administering products simultaneously.
No information is available on the safety and efficacy of this vaccine when used with
any other veterinary medicinal product except the products mentioned above. A
decision to use this vaccine before or after any other veterinary medicinal product
therefore needs to be made on a case by case basis.
Lyophilisate:
Store in a refrigerator (2 C – 8 C).
Do not freeze.
Protect from light.
Solvent:
Store below 25 °C if stored separately from the lyophilisate.
Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.

Medication costs adding up?

Pet insurance can cover prescription medications. Find the right policy for your pet.

Compare insurance

Find cheaper vets near you

Compare vet consultation prices in your area. Save on procedures and get a prescription to buy medications online.